Prostate‐specific antigen‐based prostate cancer screening: Past and future

@article{Alberts2015ProstatespecificAP,
  title={Prostate‐specific antigen‐based prostate cancer screening: Past and future},
  author={Arnout R Alberts and Ivo G. Schoots and Monique J. Roobol},
  journal={International Journal of Urology},
  year={2015},
  volume={22}
}
Prostate‐specific antigen‐based prostate cancer screening remains a controversial topic. Up to now, there is worldwide consensus on the statement that the harms of population‐based screening, mainly as a result of overdiagnosis (the detection of clinically insignificant tumors that would have never caused any symptoms), outweigh the benefits. However, worldwide opportunistic screening takes place on a wide scale. The European Randomized Study of Screening for Prostate Cancer showed a reduction… Expand
Screening for prostate cancer: moving forward in the molecular era.
TLDR
New screening tests and/or methods with increased specificity could reduce the number of men undergoing prostate biopsy - thus alleviating patients from the anxiety and the distress experienced by an unnecessary (negative) biopsy and minimizes the healthcare cost. Expand
Re: Prostate‐specific antigen‐based prostate cancer screening: Past and future
  • S. Birkeland
  • Medicine
  • International journal of urology : official journal of the Japanese Urological Association
  • 2016
TLDR
Although SDM approaches probably improve patients’ knowledge and decision-making, decrease PSA test utilization and perhaps would benefit the physician during a lawsuit, the effect on patient satisfaction and complaint behavior merits further investigation. Expand
Towards a better Diagnosis of Prostate Cancer: A Review of Prostate Cancer Screening Tests
Being one of the commonest cancers amongst males, better diagnostic or screening techniques can prevent lot of mortality and morbidity. Prostate cancer is one of the few cancers with better outcomeExpand
Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review
TLDR
A review of research papers published from 2009 to 2019 reporting biomarkers that identified or differentiated benign prostatic hyperplasia (BPH) from prostate cancer concludes that this validation will come through the use of multivariate panels which can assess the value of biomarker candidates in combination with clinical parameters as part of a risk prediction calculator. Expand
Risk of Prostate Cancer–related Death Following a Low PSA Level in the PLCO Trial
TLDR
Substantial risk disparities suggest appropriate screening intervals could depend on race/ethnicity, and five-year screening intervals may be appropriate for the 45% of men with PSA ≤ 1 ng/mL. Expand
Identification of genetic biomarkers in urine for early detection of prostate cancer.
TLDR
A novel noninvasive screening tool for a further in-depth selection of eligible cases for prostate biopsies which is based on sequencing somatic and hereditary HOXB13 mutations in urine samples is introduced. Expand
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia
TLDR
The ability of the biomarker panel to perform better than PSA alone in men with BPH, thus preventing unnecessary biopsies is demonstrated, and potential to limit false negatives in aggressive cancers is indicated. Expand
Current guidelines for prostate cancer screening: A systematic review and minimal core proposal.
TLDR
A minimum core of conducts was established that may be useful in the daily practice of the physician for screening for prostate cancer and there are differences between them. Expand
Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities
TLDR
The potential of nanotechnology is increasingly being realized, especially in prostate cancer research, and the most updated information is provided on the recent methods of prostate cancer screening, imaging and treatment modalities, with special emphasis on nanotheranostics and multifunctional nanoconstructs. Expand
Editorial Comment to Prostate‐specific antigen‐based prostate cancer screening: Past and future
  • S. Sakamoto
  • Medicine
  • International journal of urology : official journal of the Japanese Urological Association
  • 2015
TLDR
Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 142 REFERENCES
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.
TLDR
An individualized screening algorithm using other available prebiopsy information in addition to PSA level can result in a considerable reduction of unnecessary biopsies. Expand
Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
TLDR
The current state of prostate cancer biomarker research, including the PSA revolution, its impact on early cancer detection, the recent advances in biomarker discovery, and the future efforts that promise to improve clinical management of this disease are reviewed. Expand
Risk-based prostate cancer screening.
TLDR
PSA testing may serve as the foundation for a more risk-based assessment and the decision to undergo early PSA testing should be a shared one between the patient and his physician based on information balancing its advantages and disadvantages. Expand
Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.
  • E. Basch, T. Oliver, +7 authors R. Nam
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
There is evidence to suggest that men with longer life expectancy may benefit from PSA testing, and several population-based studies have shown increasing rates of infectious complications after prostate biopsy, which is a concern. Expand
Updated Japanese Urological Association Guidelines on prostate‐specific antigen‐based screening for prostate cancer in 2010
  • Kazuto Ito, S. Naito, +14 authors K. Okihara
  • Medicine
  • International journal of urology : official journal of the Japanese Urological Association
  • 2010
TLDR
PSA screening, which can reduce the risk of death as a result of prostate cancer, should be offered to all men at risk of developing prostate cancer with fact sheets showing updated benefits and drawbacks of screening for prostate cancer. Expand
Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies
TLDR
Compared with standard screening, PSA screening strategies that use higher thresholds for biopsy referral for older men and that screen men with low PSA levels less frequently can reduce harms while preserving lives. Expand
Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
TLDR
PCa screening as conducted in the Rotterdam section of the ERSPC can reduce the risk of dying from PCa up to 51% for an individual man choosing to be screened repeatedly compared with a man who was not screened. Expand
Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
TLDR
Clinicians caring for men, especially African-American men and those with positive family histories, should provide information about potential benefits and risks of prostate cancer screening, and the limitations of current evidence for screening, in order to maximize informed decision making. Expand
Screening for prostate cancer.
TLDR
It is insufficient, at present, to recommend routine population screening because of the lack of evidence that this would improve either survival or the quality of men’s lives, according to most reviews of the scientific evidence. Expand
Early detection of prostate cancer: AUA Guideline.
TLDR
The Panel recommended shared decision-making for men age 55 to 69 years considering PSA-based screening, a target age group for whom benefits may outweigh harms, and modeled data suggested that a screening interval of two years or more may be preferred to reduce the harms of screening. Expand
...
1
2
3
4
5
...